Which has higher valuation and earnings, IRON or OKYO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.58 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is IRON or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% OKYO Pharma N/A N/A N/A

Do analysts prefer OKYO or YDES?

OKYO Pharma presently has a consensus target price of $5.67, indicating a potential upside of 239.32%. Given OKYO Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe OKYO Pharma is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, OKYO or YDES?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A YD Bio N/A N/A N/A N/A N/A

Is OKYO or YDES more profitable?

Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A YD Bio N/A N/A N/A

Which has stronger earnings and valuation, OKYO or RNAC?

OKYO Pharma has higher earnings, but lower revenue than Cartesian Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A Cartesian Therapeutics $2.80M 103.71 -$130.30M -$5.94 N/A

Is OKYO or RNAC more profitable?

OKYO Pharma has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Cartesian Therapeutics -8,550.65% N/A -29.84%

Which has stronger valuation and earnings, AVXL or OKYO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.15 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is AVXL or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Anavex Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -11.76% -11.00% OKYO Pharma N/A N/A N/A

Which has preferable earnings and valuation, OKYO or FATE?

OKYO Pharma has higher earnings, but lower revenue than Fate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A Fate Therapeutics $6.65M 43.78 -$136.32M -$1.05 N/A

OKYO Pharma (OKYO) Competitors

$1.67 +0.12 (+7.74%)

As of 08/28/2026 04:00 PM Eastern

Compare

OKYO vs. IRON, YDES, RNAC, AVXL, and FATE

Should you buy OKYO Pharma stock or one of its competitors? OKYO Pharma's main competitors and comparable companies include Disc Medicine (IRON), YD Bio (YDES), Cartesian Therapeutics (RNAC), Anavex Life Sciences (AVXL), and Fate Therapeutics (FATE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does OKYO Pharma compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and OKYO Pharma (NASDAQ:OKYO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Disc Medicine presently has a consensus price target of $106.50, suggesting a potential upside of 33.08%. OKYO Pharma has a consensus price target of $5.67, suggesting a potential upside of 239.32%. Given OKYO Pharma's higher probable upside, analysts clearly believe OKYO Pharma is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Disc Medicine had 16 more articles in the media than OKYO Pharma. MarketBeat recorded 18 mentions for Disc Medicine and 2 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.43 beat Disc Medicine's score of 0.65 indicating that OKYO Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Disc Medicine	Positive
OKYO Pharma	Positive

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 3.8% of Disc Medicine shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Disc Medicine has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, OKYO Pharma has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market.

OKYO Pharma's return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
OKYO Pharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

Summary

OKYO Pharma beats Disc Medicine on 6 of the 11 factors compared between the two stocks.

How does OKYO Pharma compare to YD Bio?

OKYO Pharma (NASDAQ:OKYO) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, YD Bio had 2 more articles in the media than OKYO Pharma. MarketBeat recorded 4 mentions for YD Bio and 2 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.43 beat YD Bio's score of 0.29 indicating that OKYO Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
OKYO Pharma	Positive
YD Bio	Neutral

3.0% of OKYO Pharma shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
YD Bio	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
YD Bio	N/A	N/A	N/A

OKYO Pharma presently has a consensus target price of $5.67, indicating a potential upside of 239.32%. Given OKYO Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe OKYO Pharma is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

OKYO Pharma beats YD Bio on 6 of the 7 factors compared between the two stocks.

How does OKYO Pharma compare to Cartesian Therapeutics?

OKYO Pharma (NASDAQ:OKYO) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

OKYO Pharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

OKYO Pharma has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

OKYO Pharma presently has a consensus target price of $5.67, indicating a potential upside of 239.32%. Cartesian Therapeutics has a consensus target price of $32.60, indicating a potential upside of 239.58%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Cartesian Therapeutics had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 2 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.43 beat Cartesian Therapeutics' score of 1.08 indicating that OKYO Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
OKYO Pharma	Positive
Cartesian Therapeutics	Positive

OKYO Pharma has higher earnings, but lower revenue than Cartesian Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
Cartesian Therapeutics	$2.80M	103.71	-$130.30M	-$5.94	N/A

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Cartesian Therapeutics beats OKYO Pharma on 7 of the 12 factors compared between the two stocks.

How does OKYO Pharma compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

In the previous week, Anavex Life Sciences had 4 more articles in the media than OKYO Pharma. MarketBeat recorded 6 mentions for Anavex Life Sciences and 2 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.43 beat Anavex Life Sciences' score of 0.88 indicating that OKYO Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Anavex Life Sciences	Positive
OKYO Pharma	Positive

Anavex Life Sciences currently has a consensus target price of $21.33, indicating a potential upside of 613.49%. OKYO Pharma has a consensus target price of $5.67, indicating a potential upside of 239.32%. Given Anavex Life Sciences' higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

Anavex Life Sciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market.

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

OKYO Pharma's return on equity of 0.00% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-11.76%	-11.00%
OKYO Pharma	N/A	N/A	N/A

Summary

OKYO Pharma beats Anavex Life Sciences on 5 of the 9 factors compared between the two stocks.

How does OKYO Pharma compare to Fate Therapeutics?

OKYO Pharma (NASDAQ:OKYO) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

OKYO Pharma has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

In the previous week, Fate Therapeutics had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for Fate Therapeutics and 2 mentions for OKYO Pharma. Fate Therapeutics' average media sentiment score of 1.78 beat OKYO Pharma's score of 1.43 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
OKYO Pharma	Positive
Fate Therapeutics	Very Positive

OKYO Pharma has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. OKYO Pharma's return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

OKYO Pharma has higher earnings, but lower revenue than Fate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
Fate Therapeutics	$6.65M	43.78	-$136.32M	-$1.05	N/A

OKYO Pharma currently has a consensus target price of $5.67, suggesting a potential upside of 239.32%. Fate Therapeutics has a consensus target price of $5.90, suggesting a potential upside of 142.80%. Given OKYO Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe OKYO Pharma is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

OKYO Pharma beats Fate Therapeutics on 7 of the 13 factors compared between the two stocks.

Get OKYO Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKYO vs. The Competition

Export

Metric	OKYO Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$87.64M	$3.93B	$7.21B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	N/A	11.62	273.16	25.42
Price / Sales	N/A	1,369.80	630.81	94.42
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	5.57	16.92	11.08	6.36
Net Income	-$8.95M	-$22.74M	$3.48B	$349.79M
7 Day Performance	8.44%	-0.31%	0.13%	-0.80%
1 Month Performance	0.60%	9.80%	7.08%	4.13%
1 Year Performance	-28.94%	55.66%	24.67%	15.17%

OKYO Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKYO OKYO Pharma	3.066 of 5 stars	$1.67 +7.7%	$5.67 +239.3%	-28.9%	$87.64M	N/A	N/A	7	Positive News Short Interest Decrease Gap Up High Trading Volume
IRON Disc Medicine	2.3006 of 5 stars	$81.82 -0.7%	$106.50 +30.2%	+34.2%	$313.35M	N/A	N/A	30	News Coverage Analyst Downgrade Insider Trade
YDES YD Bio	N/A	$4.37 -6.6%	N/A	N/A	$309.35M	N/A	N/A	N/A
RNAC Cartesian Therapeutics	2.3213 of 5 stars	$10.21 -1.7%	$32.60 +219.4%	-4.5%	$308.70M	$2.80M	N/A	64	Positive News
AVXL Anavex Life Sciences	1.8995 of 5 stars	$3.32 -6.9%	$21.33 +543.5%	-69.0%	$307.30M	N/A	N/A	40	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKYO) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OKYO Pharma (OKYO) Competitors

OKYO vs. IRON, YDES, RNAC, AVXL, and FATE

How does OKYO Pharma compare to Disc Medicine?

Summary

How does OKYO Pharma compare to YD Bio?

Summary

How does OKYO Pharma compare to Cartesian Therapeutics?

Summary

How does OKYO Pharma compare to Anavex Life Sciences?

Summary

How does OKYO Pharma compare to Fate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OKYO Pharma (OKYO) Competitors

OKYO vs. IRON, YDES, RNAC, AVXL, and FATE

How does OKYO Pharma compare to Disc Medicine?

Do analysts rate IRON or OKYO?

Does the media prefer IRON or OKYO?

Do institutionals & insiders have more ownership in IRON or OKYO?

Which has more risk and volatility, IRON or OKYO?

Is IRON or OKYO more profitable?

Which has higher valuation and earnings, IRON or OKYO?

Summary

How does OKYO Pharma compare to YD Bio?

Does the media refer more to OKYO or YDES?

Do institutionals and insiders believe in OKYO or YDES?

Which has better valuation & earnings, OKYO or YDES?

Is OKYO or YDES more profitable?

Do analysts prefer OKYO or YDES?

Summary

How does OKYO Pharma compare to Cartesian Therapeutics?

Which has more risk & volatility, OKYO or RNAC?

Is OKYO or RNAC more profitable?

Do analysts prefer OKYO or RNAC?

Does the media favor OKYO or RNAC?

Which has stronger earnings and valuation, OKYO or RNAC?

Do institutionals & insiders have more ownership in OKYO or RNAC?

Summary

How does OKYO Pharma compare to Anavex Life Sciences?

Does the media refer more to AVXL or OKYO?

Do analysts rate AVXL or OKYO?

Which has stronger valuation and earnings, AVXL or OKYO?

Which has more volatility & risk, AVXL or OKYO?

Do institutionals and insiders have more ownership in AVXL or OKYO?

Is AVXL or OKYO more profitable?

Summary

How does OKYO Pharma compare to Fate Therapeutics?

Do institutionals & insiders have more ownership in OKYO or FATE?

Which has more volatility & risk, OKYO or FATE?

Does the media prefer OKYO or FATE?

Is OKYO or FATE more profitable?

Which has preferable earnings and valuation, OKYO or FATE?

Do analysts recommend OKYO or FATE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools